Clinical Trial Update: BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas [Phase 2]

View source ↗

Summary

Clinical trial BrUOG 354 assesses nivolumab with or without ipilimumab in ovarian and extrarenal (clear cell) carcinomas; the Phase 2 study is currently active …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Carcinoma
• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Brown University | Conditions: Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING